Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 8/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785733 | 0.92 | WDR5 (0.40) | WDR5CTSSRBP4NPC1POLB | |
| SCHEMBL784755 | 0.92 | WDR5 (0.40) | WDR5CTSSRBP4NPC1POLB | |
| SCHEMBL785216 | 0.91 | WDR5 (0.42) | WDR5CTSSRBP4NPC1POLB | |
| SCHEMBL785363 | 0.90 | WDR5 (0.37) | WDR5CTSSF10ROCK2 | |
| SCHEMBL785494 | 0.88 | CRHR1 (0.40) | WDR5CTSS | |
| SCHEMBL784059 | 0.88 | RORC (0.39) | WDR5CTSSF10ROCK2 | |
| SCHEMBL785316 | 0.87 | CTSS (0.42) | WDR5CTSSRBP4TRPV1NPC1 | |
| SCHEMBL785215 | 0.87 | CTSS (0.41) | WDR5CTSSPRMT3SMYD3F10 | |
| SCHEMBL783987 | 0.87 | WDR5 (0.40) | WDR5CTSSPDE10AF10 | |
| SCHEMBL784402 | 0.87 | CTSS (0.40) | WDR5CTSSF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | WDR5 2611/4885CTSS 824/4885RBP4 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.